Shanghai Fosun Pharmaceutical (Group) Co., Ltd. provided earnings guidance for the first half of 2013. Based on the preliminary estimates the Group's net profit attributable to the parent company is expected to increase by more than 40% as compared to the corresponding period of the previous year(RMB 701,766,957.49). The increase in the Group's net profit attributable to the parent company for the first half of 2013 is primarily due to (i) the steady growth maintained by the core businesses; and (ii) the gain on deemed disposal recognized from the dilution of equity interest resulting from the completion of placing of H shares of Sinopharm Group Co., Ltd, a company in which the company has invested, in April 2013.